Erdosteine

Erdosteine


visit www.erdosteine.net

Erdosteine is a New Chemical Entity (NCE) entirely developed by Edmond Pharma, starting from the initial synthesis to  patent coverage and international registration.

In the development phase a several molecules potentially effective in the  respiratory area were synthetized by Edmond Pharma. After a deep analysis Erdosteine has been selected as the final candidate for further development.  It has undergone  a complete programme of clinical and pharmacological studies with demonstration of unique characteristics, like:
  • Muco-modulatory activity
  • Anti-bacterial
  • Anti-inflammatory
  • Anti-oxidant

His highly diversified pharmacological profile makes Erdosteine an ideal  molecule for  the treatment of Chronic Bronchitis (CB) and Chronic Obstructive Pulmonary Disease (COPD), both in its stable form and during acute exacerbations.

Erdosteine has proved its efficacy and safety, both in adults and in children, in more than 60 clinical trials  with over 3,000 treated subjects and during more than 10 years’ experience in clinical practice worldwide.
Its clinical efficacy, combined with an excellent safety profile allows Erdosteine to be used in combination with the major  treatments available today for treating  CB and COPD.

Erdosteine is now available in 4 different formulations:
  • 150 mg / 300 mg capsules
  • 225 mg / 300 mg sachets
  • 175 mg dry syrup
  • 300 mg dispersible  tablets

Erdosteine is the only mucolytic currently  recommended in the guidelines of the American College of Chest Physicians for improving expectoration in chronic bronchitis.

In the United States, Erdosteine is currently in clinical Phase II development, with an active IND (Investigational New Drug) at the FDA.

Erdosteine holds several international patents on use and processing.
 
Erdosteine is approved and marketed as an under prescription drug in more than forty countries around the world.

Contact
Pierfrancesco Manzo - pierfrancesco.manzo@recipharm.com


Country Licensee Brand

Algeria
Argentina

Austria
Bahrain
Belgium
Bulgaria
Cambodia
Chile
China
Colombia
Costa Rica
Czech Republic
Denmark
Dominican Republic
Ecuador
Egypt
Finland
France
Georgia
Greece

Guatemala
Honduras
Hungary
Indonesia

Ireland
Israel
Italy
Jordan
Korea
Luxemburg
Mexico

Oman
Pakistan
Paraguay
Peru
Philippines

Poland
Qatar
Romania
Russian
Slovakia
Switzerland
Turkey

U.K.
Venezuela
Vietnam
Hikma Pharm.
Laboratorios Bagò
Montpellier
CSC Pharmaceuticals
Hikma Pharm.
Rottapharm Madaus
CSC Pharmaceuticals
Dexa Medica
Grunenthal Chilena
Eddingpharm
Grunenthal Colombiana
Grunenthal
Medicom
Orion Pharma
Grunenthal
Grunenthal Ecuatoriana
Global Napi
Orion Pharma
Lab. Wockhardt Pharma 2000
CSC
Faran
Bros
Grunenthal Ecuadoriana
Grunenthal Ecuadoriana
CSC Pharmaceuticals
Dexa Medica
Ferron
Galen
Megapharm
Rottapharm Madaus
Hikma Pharmaceuticals
Daewoong
Rottapharm Madaus
Productos Cientificos
A.F. Laboratorios
Hikma Pharm.
Brookes Pharmaceutical
Grunenthal Ecuadoriana
Grunenthal Peruana
OEP Philippines
GSK Philippines
Medagro
Hikma Pharmaceuticals
CSC Pharmaceuticals
CSC Pharmaceuticals
CSC Pharmaceuticals
Vifor
Sandoz
Eczacibasi Pharmaceuticals Co
Galen
Grunenthal Venezolana
Dexa Medica
Mucotec
Mucoflux
Fluidasa
Erdomed
Mucotec
Mucodox
Erdomed
Vectrine
Biopulmin
Erdotin
Dostol
Asdigan
Erdomed
Erdotin
Asdigan
Dostol
Mucotec
Erdopect
Vectrine
Erdomed
Tusselin
Theovix
Asdigan
Asdigan
Erdomed
Vectrine
Edotin
Erdotin
Erdotin
Erdotin
Mucotec
Erdos
Mucodox
Esteclin
Dostein
Mucotec
Dostin
Dostol
Dostol
Ectrin
Zertin
Erdomed
Mucotec
Erdomed
Erdomed
Erdomed
Mucofor
Erdostin
Evosten
Erdotin
Mukial
Vectrine


Erdosteine is a NCE entirely developed by Edmond Pharma,from initial laboratory synthesis to international patenting and registration